SignalXSignalX

NUVB Nuvation Bio Inc.

8-K Current Report
Filed: March 2, 2026
Health Care
Pharmaceutical Preparations
Nuvation Bio Inc. Overview

Nuvation Bio Inc. (NUVB) 8-K current report filed with SEC EDGAR on March 2, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
1 item

  • Item 2.02: Results of Operations and Financial Condition

AI Filing Analysis
8-K

Item 2.02 · Results of Operations and Financial Condition

  • • Q4 2025 earnings press release issued March 2, 2026 — full financials in Exhibit 99.1
  • • Filing covers quarter ended December 31, 2025; no figures disclosed in this item directly

Get deeper insights on Nuvation Bio Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.